Key Takeaways
- Lower Prices for Patients: Under the Pfizer deal, Americans will now pay most-favored-nation prices — the lowest rates paid in any developed nation — with discounts of up to 80% on key medicines.
- Ending Global Free Riding: For decades, foreign countries enjoyed cheaper drugs while U.S. patients footed the bill. Trump’s deal forces Big Pharma to stop subsidizing socialism abroad and start putting Americans first.
- America First Economics: By repatriating profits and leveraging trade policy, Trump is delivering real savings to taxpayers, strengthening Medicaid, and proving that tough negotiations can put patients over politics.
President Donald J. Trump just scored another win for American patients — this time against Big Pharma’s global price games. On Wednesday, Trump announced the first-ever deal with Pfizer to bring U.S. drug costs in line with the lowest paid by other developed nations, a policy known as most-favored-nation (MFN) pricing.
For decades, Americans have been stuck paying triple the price of brand-name drugs compared to other wealthy nations — effectively subsidizing Europe’s socialist health systems. “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill,” Trump said. “Four times, five times different.” That ends now.
The Pfizer agreement delivers MFN pricing to every state Medicaid program, saving taxpayers millions while strengthening care for the most vulnerable. More importantly, it requires Pfizer to repatriate profits boosted by Trump’s tough trade policies and pass those gains on to American patients.
The savings are real and immediate. Eucrisa, a topical ointment for dermatitis, will be offered at an 80% discount. Xeljanz, used for arthritis and colitis, will come at 40% off. Zavzpret, a popular migraine treatment, will sell at 50% off. Millions of Americans will feel the difference.
For too long, U.S. innovation funded the world while Americans picked up the tab. With this deal, Trump is rebalancing the system — forcing Big Pharma to stop freeloading abroad and start delivering fair prices at home.
This is America First economics in action: protecting innovation, cutting costs, and putting patients — not bureaucrats or foreign governments — at the center of healthcare.